Compare Organon & Co. Common Stock (OGN) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while State Street SPDR S&P Homebuilders ETF trades at $92.84 (market cap $1.49B). The key difference: Organon & Co. Common Stock is far larger — about 2.4× State Street SPDR S&P Homebuilders ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and State Street SPDR S&P Homebuilders ETF for 35 Days on average.
| OGN | XHB | |
|---|---|---|
Market Cap | $3.62B | $1.49B |
Volume | 2,892,999 | 1,578,908 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $121.36 |
52-Week Low | $5.70 | $92.84 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.70, up 0.69% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. Recent news highlights mixed housing data, with rising mortgage rates pressuring the sector but new legislation and institutional interest offering potential support. The ETF lacks current fundamental ratio data but tracks homebuilder stocks sensitive to economic cycles.
The outlook for XHB hinges on housing market dynamics; opportunities exist if affordability improves or construction accelerates, but risks include persistent high rates and economic slowdowns. Investor sentiment is cautious amid volatile home sales data, requiring close watch on macroeconomic indicators for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
